[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Regenerative Medicine Market - Global Outlook and Forecast 2021-2026

June 2021 | 284 pages | ID: R6BD3C94C968EN
Arizton Advisory & Intelligence

US$ 3,750.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Regenerative Medicine Market Report

The regenerative medicine market size to grow at a CAGR of around 30% during the period 2020-2026.

Increased R&D investments by pharmaceutical companies will drive the demand for regenerative medicines. Europe plays a significant role in supporting the development and authorization of these products for several genetic and rare disorders. Increased funding via several venture capitalists and governments, and private institutions contribute significantly to the global regenerative medicine market growth. The increased prevalence of diseases such as cardiovascular diseases and diabetes can drive cell and gene therapy and tissue-engineered products. With the rise in thermal burns, occupational burn accidents, and chronic wounds, regenerative medicine products will experience steady growth. Novartis and Gilead Sciences are the key companies offering various therapies to treat cancer, genetic, and rare disorders.

The following factors are likely to contribute to the growth of the regenerative medicine market during the forecast period:
  • Increase in the Patient Pool with Acute, Chronic, and Genetic Disorders
  • Strong Pipeline Portfolio of Regenerative Medicine Companies
  • Implementation of Advanced tissue-engineering Therapies Technology
  • Faster Regulatory approvals
The report considers the present scenario of the regenerative medicine market and its market dynamics for 2019?2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.

REGENERATIVE MEDICINE MARKET SEGMENTATION

The regenerative medicine market research report includes a detailed segmentation by application, products, end-users, geography. Oncology constitutes the largest portion of the global regenerative medicine market share. The development of curative therapies by CAR-T and cell and gene therapies is widely popularized in the oncology therapeutic area. The increasing global prevalence rates and the increasing rates of different types of life-threatening cancers are the most important key factors that drive the oncology segment.

Consistent innovations in gene therapies due to the increased number of clinical trials and pipeline products are driving the growth prospects. Hence, the increased inflow of funding for the development of gene therapy is one of the driving factors for the sector growth Cell therapy is the major revenue contributor. The increasing prevalence of diabetes and foot ulcers is the primary factor contributing to the growth of tissue-engineered products. The tissue-engineered product segment to grow at a CAGR of 8% by 2026.

Hospitals are likely to remain a dominant revenue contributor to the global regenerative medicine market. Around 50% of therapeutic surgeries performed in the US annually, including cardiovascular and musculoskeletal, occur in hospitals. Cancer care centers are likely to witness an incremental growth of approx. USD 10 billion by 2026. As cancer is the second leading cause of death across the globe, which is responsible for approx. 10 million deaths annually, the scope of cancer centers is growing. Key vendors are focusing more on cancer care centers than hospitals to promote their products. As the cancer centers are being covered under reimbursement schemes, the growth of these facilities is likely to increase during the forecast period.

Segmentation by Application
  • Oncology
  • Genetic Disorders
  • Dermatology
  • Musculoskeletal
  • Others
Segmentation by Product
  • Gene Therapies
  • Cell Therapies
  • Tissue-Engineered Therapies
Segmentation by End-Users
  • Hospitals
  • Cancer Care Centers
  • Wound Care Centers
  • ASCs
  • Others
INSIGHTS BY GEOGRAPHY

In North America, the acceptance of regenerative medicine is relatively higher than in other developed countries. North America to accounts for the largest market share of the global regenerative medicine market. The growth can be primarily attributed to the increasing population with different types of cancers such as non-Hodgkin lymphoma, Hodgkin lymphoma, melanoma of the skin, and leukaemia in the North American region. Furthermore, North America consists of the highest number of regenerative medicine companies, which is adding to the market growth in the region. Europe has highly developed manufacturing facilities, which is driving the market growth in the European region. Most vendors in Europe depend on external sources for expansion and R&D activities.

Segmentation by Geography
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • Japan
    • China
    • Australia
    • South Korea
    • India
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa
    • UAE
COMPETITIVE LANDSCAPE

Amgen, Bristol Myers Squibb, Dendreon, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Osiris, Organogenesis, and Vericel are the key vendors in the global regenerative medicine market. Global key players dominate the market shares due to wide distribution networks, innovative product launches, and broad product offerings. Companies are focusing on product innovations and strengthening their distribution channel to expand market presence globally. The market has developed innovative therapies in the field. For instance, Bristol Myers Squibb received approval from the US FDA for its product – Lisocel - to treat relapsed/refractory diffuse large-B cell lymphoma (DLBCL) in February 2021. Small players are collaborating with prominent players to gain a competitive advantage in the market.

Key Vendors
  • Novartis
  • Gilead Sciences
  • Amgen
  • Organogenesis
  • Bristol Myers Squibb
  • Vericle
  • Osiris Therapeutics
Other Prominent Vendors
  • Anges
  • Orchard Therapeutics
  • Orthofix
  • Integra Life Science
  • MiMedx
  • bluebird bio
  • Mesoblast
  • Avita Medical
  • Takeda Pharmaceuticals
  • Medipost
  • TissueTech
  • Misonix
  • J-TEC
  • Stempeutics
  • CO.DON
  • GC Pharma
  • Orthocell
  • Tego Science
  • Nipro
  • S-BIOMEDIC
  • APAC Biotech
  • Bio Solution
  • Chiesi Farmaceutici
  • Collplant
  • Corestem
  • Human Stem Cell Institute
  • JCR Pharmaceuticals
  • JW CreaGene
  • Nuvasive
  • Sibiono GeneTech
  • Shanghai Sunway Biotech
  • Terumo
KEY QUESTIONS ANSWERED:

1. How big is the regenerative medicine market?

2. What are the critical applications of regenerative medicine products?

3. Who are the key players in the regenerative medicine market?

4. Which segment accounted for the largest regenerative medicine market share?

5. Which region holds the largest share in the global regenerative medicine market?

6. How has the COVID-19 pandemic affected the regenerative medicine industry?
1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 Market Definition
  4.1.1 Inclusions
  4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
  4.3.1 Market Segmentation By Application
  4.3.2 Market Segmentation By Product
  4.3.3 Market Segmentation By End-users
  4.3.4 Market Segmentation by Geography

5 REPORT ASSUMPTIONS & CAVEATS

5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation

6 MARKET AT A GLANCE

7 INTRODUCTION

7.1 Overview

8 MARKET OPPORTUNITIES & TRENDS

8.1 Latest Advances In Tissue-Engineering Therapies
8.2 Robust Product Pipeline Of Regenerative Medicine Companies
8.3 Strategic Acquisitions By Regenerative Medicine Companies

9 MARKET GROWTH ENABLERS

9.1 Increase In Acute, Chronic, & Genetic Disorders
9.2 Increasing Demand For Car T-Cell Therapies
9.3 Faster Regulatory Approvals & Special Designations Of Rm Products

10 MARKET RESTRAINTS

10.1 Manufacturing, Operational, & Ethical Challenges
10.2 High Cost of Regenerative Therapies
10.3 Outbreak of The COVID-19 Pandemic

11 MARKET LANDSCAPE

11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
  11.3.1 Threat of New Entrants
  11.3.2 Bargaining Power of Suppliers
  11.3.3 Bargaining Power of Buyers
  11.3.4 Threat of Substitutes
  11.3.5 Competitive Rivalry

12 APPLICATION

12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Dermatology
  12.3.1 Market Overview
  12.3.2 Market Size & Forecast
12.4 Musculoskeletal
  12.4.1 Market Overview
  12.4.2 Market Size & Forecast
12.5 Oncology
  12.5.1 Market Overview
  12.5.2 Market Size & Forecast
12.6 Genetic Disorders
  12.6.1 Market Overview
  12.6.2 Market Size & Forecast
12.7 Other Applications
  12.7.1 Market Overview
  12.7.2 Market Size & Forecast

13 PRODUCT

13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Gene Therapy
  13.3.1 Market Overview
  13.3.2 Market Size & Forecast
13.4 Cell Therapy
  13.4.1 Market Overview
  13.4.2 Market Size & Forecast
13.5 Tissue-Engineering
  13.5.1 Market Overview
  13.5.2 Market Size & Forecast

14 END-USERS

14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Hospitals
  14.3.1 Market Overview
  14.3.2 Market Size & Forecast
14.4 Cancer Care Centers
  14.4.1 Market Overview
  14.4.2 Market Size & Forecast
14.5 Wound Care Centers
  14.5.1 Market Overview
  14.5.2 Market Size & Forecast
14.6 Ambulatory Surgical Centers
  14.6.1 Market Overview
  14.6.2 Market Size & Forecast
14.7 Others
  14.7.1 Market Overview
  14.7.2 Market Size & Forecast

15 GEOGRAPHY

15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview

16 NORTH AMERICA

16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
  16.3.1 US: Market Size & Forecast
  16.3.2 Canada: Market Size & Forecast

17 EUROPE

17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
  17.3.1 Germany: Market Size & Forecast
  17.3.2 France: Market Size & Forecast
  17.3.3 UK: Market Size & Forecast
  17.3.4 Italy: Market Size & Forecast
  17.3.5 Spain: Market Size & Forecast

18 APAC

18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
  18.3.1 Japan: Market Size & Forecast
  18.3.2 China: Market Size & Forecast
  18.3.3 Australia: Market Size & Forecast
  18.3.4 South Korea: Market Size & Forecast
  18.3.5 India: Market Size & Forecast

19 LATIN AMERICA

19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
  19.3.1 Brazil: Market Size & Forecast
  19.3.2 Mexico: Market Size & Forecast

20 MIDDLE EAST & AFRICA

20.1 Market Overview
20.2 Market Size & Forecast
20.3 Key Countries
  20.3.1 Turkey: Market Size & Forecast
  20.3.2 Saudi Arabia: Market Size & Forecast
  20.3.3 South Africa: Market Size & Forecast
  20.3.4 UAE: Market Size & Forecast

21 COMPETITIVE LANDSCAPE

21.1 Competition Overview
21.2 Market Share Analysis
  21.2.1 Novartis
  21.2.2 Gilead Sciences
  21.2.3 Amgen
  21.2.4 Dendreon
  21.2.5 Organogenesis
  21.2.6 Bristol-Myers Squibb
  21.2.7 Vericel
  21.2.8 Osiris Therapeutics
  21.2.9 F. Hoffmann-La Roche

22 KEY COMPANY PROFILES

22.1 Novartis
  22.1.1 Business Overview
  22.1.2 Product Offerings
  22.1.3 Key Strategies
  22.1.4 Key Strengths
  22.1.5 Key Opportunities
22.2 Gilead Sciences
  22.2.1 Business Overview
  22.2.2 Product Offerings
  22.2.3 Key Strategies
  22.2.4 Key Strengths
  22.2.5 Key Opportunities
22.3 Amgen
  22.3.1 Business Overview
  22.3.2 Product Offerings
  22.3.3 Key Strategies
  22.3.4 Key Strengths
  22.3.5 Key Opportunities
22.4 Organogenesis
  22.4.1 Business Overview
  22.4.2 Product Offerings
  22.4.3 Key Strategies
  22.4.4 Key Strengths
  22.4.5 Key Opportunities
22.5 Bristol-Myers Squibb
  22.5.1 Business Overview
  22.5.2 Product Offerings
  22.5.3 Key Strategies
  22.5.4 Key Strengths
  22.5.5 Key Opportunities
22.6 Vericel
  22.6.1 Business Overview
  22.6.2 Product Offerings
  22.6.3 Key Strategies
  22.6.4 Key Strengths
  22.6.5 Key Opportunities
22.7 Osiris Therapeutics
  22.7.1 Business Overview
  22.7.2 Product Offerings
  22.7.3 Key Strategies
  22.7.4 Key Strengths
  22.7.5 Key Opportunities

23 OTHER PROMINENT VENDORS

23.1 ANGES
  23.1.1 Business Overview
  23.1.2 Product Offerings
23.2 APAC Biotech
  23.2.1 Business Overview
  23.2.2 Product Offerings
23.3 Avita Medical
  23.3.1 Business Overview
  23.3.2 Product Offerings
23.4 Bio Solution
  23.4.1 Business Overview
  23.4.2 Product Offerings
23.5 bluebird bio
  23.5.1 Business Overview
  23.5.2 Product Offerings
23.6 Chiesi Farmaceutici
  23.6.1 Business Overview
  23.6.2 Product Offerings
23.7 CO.DON
  23.7.1 Business Overview
  23.7.2 Product Offerings
23.8 Collplant
  23.8.1 Business Overview
  23.8.2 Product Offerings
23.9 Corestem
  23.9.1 Business Overview
23.10 GC Pharma
  23.10.1 Business Overview
  23.10.2 Product Offerings
23.11 Human Stem Cell Institute
  23.11.1 Business Overview
  23.11.2 Product Offerings
23.12 Integra Life Sciences
  23.12.1 Business Overview
  23.12.2 Product Offerings
23.13 JCR Pharmaceuticals
  23.13.1 Business Overview
  23.13.2 Product Offerings
23.14 J-TEC
  23.14.1 Business Overview
  23.14.2 Product Offerings
23.15 JW CreaGene
  23.15.1 Business Overview
  23.15.2 Product Offerings
23.16 MEDIPOST
  23.16.1 Business Overview
  23.16.2 Product Offerings
23.17 MiMedx
  23.17.1 Business Overview
  23.17.2 Product Offerings
23.18 Misonix
  23.18.1 Business Overview
  23.18.2 Product Offerings
23.19 Mesoblast
  23.19.1 Business Overview
  23.19.2 Product Offerings
23.20 Nipro
  23.20.1 Business Overview
  23.20.2 Product Offerings
23.21 Nuvasive
  23.21.1 Business Overview
  23.21.2 Product Offerings
23.22 Orchard Therapeutics
  23.22.1 Business Overview
  23.22.2 Product Offerings
23.23 Orthifix
  23.23.1 Business Overview
  23.23.2 Product Offerings
23.24 Orthocell
  23.24.1 Business Overview
  23.24.2 Product Offerings
23.25 S.BIOMEDICS
  23.25.1 Business Overview
  23.25.2 Product Offerings
23.26 Sibiono GeneTech
  23.26.1 Business Overview
  23.26.2 Product Offerings
23.27 Shanghai Sunway Biotech
  23.27.1 Business Overview
  23.27.2 Product Offerings
23.28 Stempeutics
  23.28.1 Business Overview
  23.28.2 Product Offerings
23.29 Takeda Pharmaceuticals
  23.29.1 Business Overview
  23.29.2 Product Offerings
23.30 Tego Science
  23.30.1 Business Overview
  23.30.2 Product Offerings
23.31 Terumo
  23.31.1 Business Overview
  23.31.2 Product Offerings
23.32 Tissuetech
  23.32.1 Business Overview
  23.32.2 Product Offerings

24 REPORT SUMMARY

24.1 Key Takeaways
24.2 Strategic Recommendations

25 QUANTITATIVE SUMMARY

25.1 Market By Geography
25.2 Market By Application
25.3 Market By Product
25.4 Market By End-User

26 APPENDIX

26.1 Abbreviations

LIST OF EXHIBITS

Exhibit 1 Segmentation of Global Regenerative Medicine Market
Exhibit 2 Market Size Calculation Approach 2020
Exhibit 3 Regenerative Medicine Total Global Financing 2017–2020 ($ billion)
Exhibit 4 Latest Advances in Tissue-engineering Therapies
Exhibit 5 Robust Product Pipeline of Regenerative Medicine Companies
Exhibit 6 Number of Regenerative Medicine Products in Different Therapeutic Areas in Various Phases of Clinical Trials
Exhibit 7 Strategic Acquisitions by Regenerative Medicine Companies
Exhibit 8 Increase in Acute, Chronic, & Genetic Disorders
Exhibit 9 Acute Lymphoblastic Leukemia Cases Worldwide 1990-2020
Exhibit 10 Region-wise Prevalence of Non-Hodgkin Lymphoma from 2015 to 2020
Exhibit 11 Increasing Demand for CAR T-cell and Gene Therapies
Exhibit 12 Number of CAR T-Cell Therapies in Clinical Trials (January 2018)
Exhibit 13 Major Vendors engaged in CAR T-Cell Therapies Development
Exhibit 14 Faster Regulatory Approvals & Special Designations of RM Products
Exhibit 15 Manufacturing, Operational, & Ethical Challenges
Exhibit 16 Manufacturing & Operational Challenges Associated with Regenerative Medicine Products for Vendors
Exhibit 17 High Cost of Regenerative Therapies
Exhibit 18 Cost of Select Marketed Cell & Gene Therapy Products (lacs)
Exhibit 19 Outbreak of the COVID-19 Pandemic
Exhibit 20 Global Regenerative Medicine Market 2020–2026 ($ million)
Exhibit 21 Global Regenerative Medicine Market by Product: 2020&2026 Percentage Share Comparison
Exhibit 22 Global Regenerative Medicine Market by Application: 2020& 2026 Percentage Share Comparison
Exhibit 23 Global Regenerative Medicine Market by End-users 2020& 2026 Percentage Share Comparison
Exhibit 24 Global Regenerative Medicine Market by Geography: 2020 & 2026 Percentage Share Comparison
Exhibit 25 Five Forces Analysis 2020
Exhibit 26 Incremental Growth by Application 2020 & 2026
Exhibit 27 Global Regenerative Medicine Market by Application
Exhibit 28 Global Regenerative Medicine Market by Application: Incremental growth
Exhibit 29 Global Regenerative Medicine Market by Application: Absolute Growth
Exhibit 30 Distribution of Wound Types in Various Hospitals and Wound Care Centres (%)
Exhibit 31 Global Regenerative Medicine Market by Dermatology Incremental Growth Vs Absolute Growth
Exhibit 32 Global Regenerative Medicine Market by Dermatology 2020–2026 ($ million)
Exhibit 33 Global Regenerative Medicine Market by Musculoskeletal Application: Incremental Growth Vs Absolute Growth
Exhibit 34 Global Regenerative Medicine Market by Musculoskeletal Application 2020–2026 ($ million)
Exhibit 35 New Types of Cancer Cases reported Worldwide (2020)
Exhibit 36 Number of Products in Clinical Trials in Oncology Application
Exhibit 37 Global Regenerative Medicine Market by Oncology Application: Incremental Growth Versus Absolute Growth
Exhibit 38 Global Regenerative Medicine Market by Oncology Application 2020–2026 ($ million)
Exhibit 39 Global Regenerative Medicine Market by Genetic Disorders: Incremental Growth Vs Absolute Growth
Exhibit 40 Global Regenerative Medicine Market by Genetic Disorders 2020–2026 ($ million)
Exhibit 41 Global Regenerative Medicine Market by Other Applications: Incremental Growth Vs Absolute Growth
Exhibit 42 Global Regenerative Medicine Market by Other Applications 2020–2026 ($ million)
Exhibit 43 Incremental Growth by Product 2020 & 2026
Exhibit 44 Global Regenerative Medicine Market by Product
Exhibit 45 Global Regenerative Medicine Market by Product – Incremental Growth
Exhibit 46 Global Regenerative Medicine Market by Product – Absolute Growth
Exhibit 47 Important Events in the Development of Gene Therapy
Exhibit 48 Global Funding for Development of Gene Therapy 2017–2020 ($ billion)
Exhibit 49 Global Regenerative Medicine Market by Gene Therapy Incremental Growth Vs Absolute Growth
Exhibit 50 Global Regenerative Medicine Market by Gene Therapy 2020–2026 ($ million)
Exhibit 51 Global Funding for Development of Cell Therapy 2017–2020 ($ billion)
Exhibit 52 Global Regenerative Medicine Market by Cell Therapy Incremental Growth Vs. Absolute Growth
Exhibit 53 Global Regenerative Market by Cell Therapy 2020–2026 ($ million)
Exhibit 54 Global Funding for Development of Tissue-engineering Products 2017–2020 (million)
Exhibit 55 Prevalence of Diabetic Foot Ulcers in Different Regions
Exhibit 56 Global Regenerative Medicine Market by Tissue-engineered Products: Incremental Growth Vs. Absolute Growth
Exhibit 57 Global Regenerative Medicine Market by Tissue-engineered Products 2020–2026 ($ million)
Exhibit 58 Incremental Growth by End-users 2020 & 2026
Exhibit 59 Global Regenerative Medicine Market by End-users
Exhibit 60 Global Regenerative Medicine by End-users– Incremental Growth
Exhibit 61 Global Regenerative Medicine by End-users– Absolute Growth
Exhibit 62 Global Regenerative Medicine Market by Hospitals Incremental Growth Vs Absolute Growth
Exhibit 63 Global Regenerative Medicine Market by Hospitals 2020–2026 ($ million)
Exhibit 64 Global Regenerative Medicine Market by Cancer Care Centers Incremental Growth Vs Absolute Growth
Exhibit 65 Global Regenerative Medicine Market by Cancer Care Centers 2020–2026 ($ million)
Exhibit 66 Global Regenerative Medicine Market by Wound Care Centers Incremental Growth Vs Absolute Growth
Exhibit 67 Global Regenerative Medicine Market by Wound Care Centers 2020–2026 ($ million)
Exhibit 68 Percentages of Specialties in Ambulatory Service Centers
Exhibit 69 Global Regenerative Medicine Market by Ambulatory Surgical Centers Incremental Growth Vs. Absolute Growth
Exhibit 70 Global Regenerative Medicine Market by Ambulatory Service Centers 2020–2026 ($ million)
Exhibit 71 Global Regenerative Medicine Market by Others: Incremental Growth Vs Absolute Growth
Exhibit 72 Global Regenerative Medicine Market by Others End-users 2020–2026 ($ million)
Exhibit 73 Incremental Growth by Geography 2019 & 2025
Exhibit 74 Global Regenerative Medicine Market by Geography
Exhibit 75 Global Regenerative Medicine by Geography– Incremental Growth
Exhibit 76 Global Regenerative Medicine by Geography – Absolute Growth
Exhibit 77 Regenerative Medicine Market in North America: Key countries ($ million)
Exhibit 78 New Cancer Cases Reported in North America 2020
Exhibit 79 Regenerative Medicine Market in North America: Incremental Growth & Absolute Growth Comparisons
Exhibit 80 Regenerative Medicine Market in North America 2020–2026 ($ million)
Exhibit 81 Incremental Growth in North America 2020 & 2026
Exhibit 82 Estimated Number of New Cancer Cases in US 2017–2021
Exhibit 83 Major Regenerative Medicine Companies R&D Investments in 2020 ($ million)
Exhibit 84 Regenerative Medicine Market in US 2020–2026 ($ million)
Exhibit 85 Estimated Number of New Cancer Cases in Canada in 2020
Exhibit 86 Regenerative Medicine Market in Canada 2020–2026 ($ million)
Exhibit 87 Reported Cancer Cases in Europe 1995 & 2020 (million)
Exhibit 88 Number of Products designated Under PRIME Designation in Several Therapeutic Areas by EMA (2021)
Exhibit 89 Regenerative Medicine Market in Europe 2020–2026 ($ million)
Exhibit 90 Incremental Growth in Europe 2020 & 2026
Exhibit 91 Number of New Types of Cancer Cases in Germany (2020)
Exhibit 92 New Types of Cancer Cases Detected in France (2020)
Exhibit 93 Regenerative Medicine Market in France 2020–2026 ($ million)
Exhibit 94 Estimated Number of People living with Cancer by 2030 (million)
Exhibit 95 Number of Different Types of Cancer Cases in UK (2020)
Exhibit 96 Regenerative Medicine Market in UK 2020–2026 ($ million)
Exhibit 97 Per Capita Healthcare Expenditure in Italy between 2016 and 2018 ($)
Exhibit 98 Number of Different Types of Cancer reported in Italy (2020)
Exhibit 99 Regenerative Medicine Market in Italy 2020–2026 ($ million)
Exhibit 100 Number of Different Types of Cancers Cases reported in Spain (2020)
Exhibit 101 Regenerative Medicine Market in Spain 2020–2026 ($ million)
Exhibit 102 Regenerative Medicine Market in APAC: Key Countries ($ million)
Exhibit 103 Number of New Cancer Cases reported in APAC (2020)
Exhibit 104 Annual Health Care Costs (direct & indirect) of CVDs in APAC ($ billion)
Exhibit 105 Regenerative Medicine Market in APAC 2020–2026 ($ million)
Exhibit 106 Incremental Growth in APAC 2020 & 2026
Exhibit 107 Number of New Cancer Cases reported in Japan (2020)
Exhibit 108 Regenerative Medicine Market in Japan 2020–2026 ($ million)
Exhibit 109 Number of new Types of Cancer Cases reported in China (2020)
Exhibit 110 Regenerative Medicine Market in China 2020–2026 ($ million)
Exhibit 111 Number of New Types of Cancer Cases reported in Australia (2020)
Exhibit 112 Regenerative Medicine Market in Australia 2020–2026 ($ million)
Exhibit 113 Number of New Types of Cancers in South Korea (2020)
Exhibit 114 Regenerative Medicine Market in South Korea 2020–2026 ($ million)
Exhibit 115 Number of New Types of Cancer Cases reported in India (2020)
Exhibit 116 Regenerative Medicine Market in India 2020–2026 ($ million)
Exhibit 117 Regenerative Medicine Market in Latin America: Incremental Growth & Absolute Growth Comparison
Exhibit 118 New Types of Cancer Cases reported in Latin America (2020)
Exhibit 119 Country-wise Cancer Cases Detected in Latin America (2020)
Exhibit 120 Regenerative Medicine Market in Latin America: Key Countries ($ million)
Exhibit 121 Regenerative Medicine Market in Latin America 2020–2026 ($ million)
Exhibit 122 Incremental Growth in Latin America 2020 & 2026
Exhibit 123 Number of New Types of Cancer Cases reported in Brazil (2020)
Exhibit 124 Regenerative Medicine Market in Brazil 2020–2026 ($ million)
Exhibit 125 Number of New Types of Cancer Cases reported in Mexico (2020)
Exhibit 126 Mexico Per Capita Health Expenditure during 2016–2018 ($)
Exhibit 127 Regenerative Medicine Market in Mexico 2020–2026 ($ million)
Exhibit 128 Cancer Cases in Different Countries of Middle East African Region in 2020
Exhibit 129 Regenerative Medicine Market in Middle East & Africa: Incremental Growth & Absolute Growth Comparison
Exhibit 130 Regenerative Medicine Market in Middle East & Africa: Key Countries ($ million)
Exhibit 131 Regenerative Medicine Market in Middle East & Africa 2020–2026 ($ million)
Exhibit 132 Incremental Growth in Middle East & Africa 2020 & 2026
Exhibit 133 Number of New Cancer Cases reported in Turkey (2020)
Exhibit 134 Regenerative Medicine Market in Turkey 2020–2026($ million)
Exhibit 135 Per Capita Healthcare Expenditure in Saudi Arabia 2016-2018 ($)
Exhibit 136 Number of New Types of Cancer Cases reported in Saudi Arabia (2020)
Exhibit 137 Regenerative Medicine Market in Saudi Arabia 2020–2026 ($ million)
Exhibit 138 Percentage of Incidence and Mortality Rates by of Cancer Types in South Africa
Exhibit 139 Regenerative Medicine Market in South Africa 2020–2026 ($ million)
Exhibit 140 Number of New Types of Cancer Cases reported in UAE (2020)
Exhibit 141 Regenerative Medicine Market in UAE 2020–2026 ($ million)
Exhibit 142 Novartis Revenue 2018–2020 ($ million)
Exhibit 143 Novartis R&D Expenditure 2018–2020 ($ million)
Exhibit 144 Novartis Segments Revenue 2018–2020 ($ million)
Exhibit 145 Novartis Sales Breakdown by Region 2108–2020 ($ million)
Exhibit 146 Gilead Sciences Revenue 2017–2020 ($ billion)
Exhibit 147 Gilead Sciences’ R&D Expenditure 2017–2020 ($ billion)
Exhibit 148 Gilead Sciences Segments Revenue 2018–2020 ($ billion)
Exhibit 149 Gilead Sciences Sales Breakdown by Key Counties & Region 2108–2020 ($ billion)
Exhibit 150 Amgen Revenue during 2018–2020 (million)
Exhibit 151 Amgen’s R&D Expenditure 2018–2020 ($ million)
Exhibit 152 Organogenesis Revenue 2017–2020 ($ million)
Exhibit 153 Bristol-Myers Squibb Revenue 2018–2020 ($ million)
Exhibit 154 Bristol-Myers Squibb’s R&D Expenditure 2018–2020 ($ million)
Exhibit 155 Vericel Revenue during 2018–2020 ($ million)
Exhibit 156 Product-wise Revenues of Vericel in 2018-2020 ($ million)
Exhibit 157 Osiris Revenue 2017–2019 ($ million)
Exhibit 158 Osiris Sales & Marketing Expenditure 2017–2018 ($ million)
Exhibit 159 Product-wise Revenues of Osiris Therapeutics 2017–2018 ($ million)

LIST OF TABLES

Table 1 Key Caveats
Table 2 Currency Conversion 2013?2020
Table 3 Additive Manufacturing Techniques for Scaffolds Fabrication
Table 4 Pipeline products in Regenerative medicine
Table 5 Regenerative Medicine Products under RMAT Designation
Table 6 Regenerative Medicines under PRIME Designation
Table 7 Regenerative Medicines under SAKIGAKE Designation
Table 8 Major M&A in Regenerative Medicine Market between 2014 & 2016
Table 9 Recent Acquisitions in Global Regenerative Medicine Market
Table 10 CAR T-Cell Investigational Products
Table 11 Guidance and Key Features by US FDA Regulatory Framework
Table 12 Product Approvals & Launch Details
Table 13 Recent Regenerative Medicine Products under RMAT Designation 2020–2021
Table 14 Cost of Kymriah in Different Regions
Table 15 Major Vendors offering Regenerative Products in Dermatology
Table 16 Pipeline Products of Key Vendors in Musculoskeletal Application
Table 17 Major Vendors offering Regenerative Products in Musculoskeletal Application
Table 18 Expedited Product Approvals in Oncology in 2020
Table 19 Major Vendors offering Regenerative Products in Oncology Application
Table 20 Expedited Product Approvals for Genetic Disorders in 2020
Table 21 Major Vendors offering Regenerative Products for Genetic Disorders
Table 22 Significant Players offering Regenerative Products for Other Diseases
Table 23 Key Players offering Gene Therapy Products for Several Indications
Table 24 Key Players offering Cell Therapy Products for Several Indications
Table 25 Key Vendors offering Products in Tissue-engineering Products
Table 26 List of Gene Therapy Areas Active Research Institutes in US and Canada
Table 27 Recent US FDA approved Regenerative Medicines including Cell and Gene Therapies
Table 28 Recent Regenerative Medicine Products approved by Health Canada
Table 29 Recent ATMP’s approved in Europe by European Medicines Agency
Table 30 Recent Products under SAKIGAKE Designation
Table 31 Recent Regenerative Product Approvals in Japan
Table 32 Regenerative Medicine Products approved in South Korea
Table 33 Key Competitive Factors in Global Regenerative Medicine Market
Table 34 Global Regenerative Medicine Market: Vendors Ranking
Table 35 Global Gene Therapy Market: Vendors Ranking
Table 36 Global Cell Therapy Market: Vendors Ranking
Table 37 Global Tissue-Engineered Products Market: Vendors Ranking
Table 38 Novartis: Major Product Offerings
Table 39 Gilead Sciences: Major Product Offerings
Table 40 Amgen: Major Product Offerings
Table 41 Organogenesis: Product Offerings
Table 42 Bristol Myers Squibb: Product Offerings
Table 43 Vericel: Product Offerings
Table 44 Osiris Therapeutics: Product Offerings
Table 45 Anges: Major Product Offerings
Table 46 APAC Biotech: Major Product Offerings
Table 47 Avita Medical: Major Product Offerings
Table 48 Bio Solution: Major Product Offerings
Table 49 bluebird bio: Major Product Offerings
Table 50 CHIESI FARMACEUTICI: Major Product Offerings
Table 51 CO.DON: Major Product Offerings
Table 52 COLLPLANT: Major Product Offerings
Table 53 CoreStem: Major Product Offerings
Table 54 GC Pharma: Major Product Offerings
Table 55 Human Stem Cell Institute: Major Product Offerings
Table 56 Integra Life sciences: Major Product Offerings
Table 57 JCR Pharmaceutical: Major Product Offerings
Table 58 J-TEC: Major Product Offerings
Table 59 JW CreaGene: Major Product Offerings
Table 60 Medipost: Major Product Offerings
Table 61 MiMedx: Major Product Offerings
Table 62 Misonix: Major Product Offerings
Table 63 Mesoblast: Major Product Offerings in its Pipeline
Table 64 Nipro: Major Product Offerings
Table 65 NuVasive: Major Product Offerings
Table 66 Orchard Therapeutics: Major Product Offerings
Table 67 Orthofix: Major Product Offerings
Table 68 Orthocell: Major Product Offerings
Table 69 S-BIOMEDICS: Major Product Offerings
Table 70 Sibiono GeneTech: Major Product Offerings
Table 71 Shanghai Sunway Biotech: Major Product Offerings
Table 72 Stempeutics: Major Product Offerings
Table 73 Takeda Pharmaceuticals: Major Product Offerings
Table 74 Tego Science: Major Product Offerings
Table 75 Terumo: Major Product Offerings
Table 76 TissueTech: Major Product Offerings
Table 77 Global Regenerative Medicine Market by Geography 2020–2026($ million)
Table 78 Global Regenerative Medicine Market by Geography 2020–2026(%)
Table 79 Global Regenerative Medicine Market by Application 2020?2026 ($ million)
Table 80 Global Regenerative Medicine Market by Application 2020?2026 (%)
Table 81 Global Regenerative Medicine Market by Product 2020–2026($ million)
Table 82 Global Regenerative Medicine Market by Product 2020–2026 (%)
Table 83 Global Regenerative Medicine Market by End-user 2020–2026($ million)
Table 84 Global Regenerative Medicine Market by End-users 2020–2026(%)


More Publications